Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Acute myeloid leukaemia (AML) is a major haematopoietic malignancy characterized by the proliferation of a malignant clone of myeloid progenitor cells. A reciprocal translocation, t(8;21)(q22;q22), observed in the leukaemic cells of approximately 40% of patients with the M2 subtype of AML disrupts both the AML1 (CBFA2) gene on chromosome 21 and the ETO (MTG8) gene on chromosome 8 (refs 3-5). A chimaeric protein is synthesized from one of the derivative chromosomes that contains the N terminus of the AML1 transcription factor, including its DNA-binding domain, fused to most of ETO, a protein of unknown function. We generated mice that mimic human t(8;21) with a "knock-in' strategy. Mice heterozygous for an AML1-ETO allele (AML1-ETO/+) die in midgestation from haemorrhaging in the central nervous system and exhibit a severe block in fetal liver haematopoiesis. This phenotype is very similar to that resulting from homozygous disruption of the AML1 (Cbfa2) or Cbfb genes, indicating that AML1-ETO blocks normal AML1 function. However, yolk sac cells from AML1-ETO/+ mice differentiated into macrophages in haematopoietic colony forming unit (CFU) assays, unlike Cbfa2-/- or Cbfb-/-cells, which form no colonies in vitro. This indicates that AML1-ETO may have other functions besides blocking wild-type AML1, a property that may be important in leukaemogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, AML1-ETO and inv (16) transgenic mice display a phenotype similar to that of AML-1 (CBF-␣)-and CBF--deficient mice, as they die during embryogenesis from central nervous system hemorrhages and exhibit severe blocks in fetal liver hematopoiesis (6,52,69,70,74).”
From The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation (1998) · cites this paper as [74]
In the citing paper
“These results were corroborated by the generation of AML-1-ETO”
From The t(8;21) Fusion Product, AML-1–ETO, Associates with C/EBP-α, Inhibits C/EBP-α-Dependent Transcription, and Blocks Granulocytic Differentiation (1998) · cites this paper as [74]
In the citing paper
“RUNX1 is frequently inactivated by mutation or translocation in the myeloid cancers myelodysplastic syndrome and acute myeloid leukemia (AML)3 (∼20% of cases)”
From Runx1 regulation of Pu.1 corepressor/coactivator exchange identifies specific molecular targets for leukemia differentiation therapy (2014) · cites this paper as [7]
Citations
Cites
Targeted mutation of the DNA methyltransferase gene results in embryonic lethality
Li, E., Bestor, T. H., & Jaenisch, R. (1992) · Cell · doi:10.1016/0092-8674(92)90611-f · Cited by 3,984
Okuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856
Altering the Genome by Homologous Recombination
Capecchi, M. R. (1989) · Science · doi:10.1126/science.2660260 · Cited by 1,594
An early haematopoietic defect in mice lacking the transcription factor GATA-2
Tsai, F.-Y., Keller, G., Kuo, F. C., Weiss, M., Chen, J., Rosenblatt, M., Alt, F. W., & Orkin, S. H. (1994) · Nature · doi:10.1038/371221a0 · Cited by 1,237
Wang, Q., Stacy, T., Binder, M., Marin-Padilla, M., Sharpe, A. H., & Speck, N. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3444 · Cited by 1,178
Self-citationMiyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872
Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732
Erickson, P., Gao, J., Chang, K., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J., & Drabkin, H. (1992) · Blood · doi:10.1182/blood.v80.7.1825.1825 · Cited by 631
The CBFβ Subunit Is Essential for CBFα2 (AML1) Function In Vivo
Wang, Q., Stacy, T., Miller, J. D., Lewis, A. F., Gu, T.-L., Huang, X., Bushweller, J. H., Bories, J.-C., Alt, F. W., Ryan, G., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81389-6 · Cited by 621
Self-citationGiese, K., Kingsley, C., Kirshner, J. R., & Grosschedl, R. (1995) · Genes & Development · doi:10.1101/gad.9.8.995 · Cited by 541
Research works printed but not linked: 1
- Rowley, J.D. Biological implications of consistent chromosome rearrangements in leukemia and lymphoma. Cancer Res. 44, 3159–3168 (1984).
Cited by
Items 101–200 of 344
Vaillant, F., Blyth, K., Terry, A., Bell, M., Cameron, E. R., Neil, J. C., & Stewart, M. A. (1999) · Oncogene · doi:10.1038/sj.onc.1203202 · Cited by 93
Cuenco, G. M., Nucifora, G., & Ren, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030421197 · Cited by 87
Runx1/AML1 in Normal and Abnormal Hematopoiesis
Yamagata, T., Maki, K., & Mitani, K. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05075 · Cited by 93
Dunne, J., Cullmann, C., Ritter, M., Martinez-Soria, N., Drescher, B., Debernardi, S., Skoulakis, S., Hartmann, O., Krause, M., Krauter, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209638 · Cited by 94
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
Larizza, L., Magnani, I., & Beghini, A. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190400007565 · Cited by 91
Ganly, P. S., Walker, L. C., & Morris, C. M. (2004) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/1042819031000139611 · Cited by 87
RUNX1 Mutations in Inherited and Sporadic Leukemia
Bellissimo, D. C., & Speck, N. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00111 · Cited by 84
Self-citationKanno, Y., Kanno, T., Sakakura, C., Bae, S.-C., & Ito, Y. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.4252 · Cited by 80
Reeler: new tales on an old mutant mouse
D'Arcangelo, G., & Curran, T. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199803)20:3<235::aid-bies7>3.0.co;2-q · Cited by 153
Runx1Protects Hematopoietic Stem/Progenitor Cells from Oncogenic Insult
Motoda, L., Osato, M., Yamashita, N., Jacob, B., Chen, L. Q., Yanagida, M., Ida, H., Wee, H., Sun, A. X., Taniuchi, I., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0061 · Cited by 82
Cuenco, G. M., & Ren, R. (2001) · Oncogene · doi:10.1038/sj.onc.1205095 · Cited by 83
Animal models of acute myelogenous leukaemia – development, application and future perspectives
McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2005) · Leukemia · doi:10.1038/sj.leu.2403670 · Cited by 84
Genetic manipulation of AML1-ETO–induced expansion of hematopoietic precursors in a Drosophila model
Sinenko, S. A., Hung, T., Moroz, T. P., Tran, Q.-M., Sidhu, S., Cheney, M. D., Speck, N. A., & Banerjee, U. K. (2010) · Blood · doi:10.1182/blood-2010-03-276998 · Cited by 85
Self-citationAsou, N. (2003) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00003-3 · Cited by 80
Feng, J., Iwama, A., Satake, M., & Kohu, K. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07632.x · Cited by 79
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
Hatlen, M. A., Wang, L., & Nimer, S. D. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0206-6 · Cited by 81
Marcucci, G., Geyer, S. M., Laumann, K. M., Zhao, W., Bucci, D. M., Uy, G. L., Blum, W. G., Eisfeld, A., Pardee, T. S., Wang, E. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000492 · Cited by 75
Gardini, A., Cesaroni, M., Luzi, L., Okumura, A. J., Biggs, J. R., Minardi, S. P., Venturini, E., Zhang, D., Pelicci, P. G., & Alcalay, M. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000275 · Cited by 80
Self-citationSolution structure of core binding factor beta and map of the CBF alpha binding site.
Bushweller, J. H., Huang, X., Peng, J. W., & Speck, N. A. (1999) · Nature Structural Biology · doi:10.1038/10670 · Cited by 77
Self-citationSchwer, H., Liu, L., Zhou, L., Little, M.-T., Pan, Z., Hetherington, C. J., & Zhang, D. (2000) · Genomics · doi:10.1006/geno.2000.6148 · Cited by 74
Self-citationRegulation and regulatory parameters of histone modifications
Davie, J., & Chadee, D. N. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(1998)72:30/31+<203::aid-jcb25>3.0.co;2-4 · Cited by 125
PEBP2-β/CBF-β–dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis
Wee, H.-J., Voon, D. C.-C., Bae, S.-C., & Ito, Y. (2008) · Blood · doi:10.1182/blood-2008-01-134122 · Cited by 69
Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects
Goyama, S., & Mulloy, J. C. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0858-z · Cited by 84
Core binding factor at the crossroads: Determining the fate of the HSC
Link, K. A., Chou, F., & Mulloy, J. C. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21950 · Cited by 72
Beghini, A., Magnani, I., Ripamonti, C. B., & Larizza, L. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200168 · Cited by 69
Altered affinity of CBFβ-SMMHC for Runx1 explains its role in leukemogenesis
Lukasik, S. M., Zhang, L., Corpora, T., Tomanicek, S., Li, Y., Kundu, M., Hartman, K. L., Liu, P., Laue, T. M., Biltonen, R. L., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb831 · Cited by 77
Self-citationComplementing mutations in core binding factor leukemias: from mouse models to clinical applications
Müller, A. M. S., Duque‐Afonso, J., Shizuru, J. A., & Lübbert, M. (2008) · Oncogene · doi:10.1038/onc.2008.196 · Cited by 80
Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity
Aho, T. L. T., Sandholm, J. A., Peltola, K. J., Ito, Y., & Koskinen, P. J. (2006) · BMC Cell Biology · doi:10.1186/1471-2121-7-21 · Cited by 70
Normal and transforming functions of RUNX1: A perspective
Mikhail, F. M., Sinha, K. K., Saunthararajah, Y., & Nucifora, G. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20538 · Cited by 81
Okuda, T., Takeda, K., Fujita, Y., Nishimura, M., Yagyu, S., Yoshida, M., Akira, S., Downing, J. R., & Abe, T. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.1.319-328.2000 · Cited by 66
ISG15, not just another ubiquitin-like protein
Kim, K. I., & Zhang, D. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)01216-6 · Cited by 73
Self-citationMelnick, A. M., Carlile, G. W., McConnell, M. J., Polinger, A., Hiebert, S. W., & Licht, J. D. (2000) · Blood · doi:10.1182/blood.v96.12.3939 · Cited by 70
Mandoli, A., Singh, A. A., Prange, K. H. M., Tijchon, E. J. H., Oerlemans, M. M. P., Dirks, R. A. M., ter Huurne, M., Wierenga, A. T. J., Janssen‐Megens, E. M., Berentsen, K., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.082 · Cited by 69
Mouse models for human disease
Hardouin, S., & Nagy, A. (2000) · Clinical Genetics · doi:10.1034/j.1399-0004.2000.570401.x · Cited by 71
The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO
Peterson, L. F., Yan, M., & Zhang, D.-E. (2007) · Blood · doi:10.1182/blood-2006-03-012575 · Cited by 61
Self-citationThe Molecular Genetics of Recurring Chromosome Abnormalities in Acute Myeloid Leukemia
Hayashi, Y. (2000) · Seminars in Hematology · doi:10.1016/s0037-1963(00)90017-9 · Cited by 64
Epigenetic consequences of AML1–ETO action at the human c‐FMS locus
Follows, G., Tagoh, H., Lefevre, P., Hodge, D., Morgan, G. J., & Bonifer, C. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg250 · Cited by 67
The Runx genes as dominant oncogenes
Cameron, E. R., Blyth, K., Hanlon, L., Kilbey, A., Mackay, N. A., Stewart, M. A., Terry, A., Vaillant, F., Wotton, S., & Neil, J. C. (2003) · Blood Cells Molecules and Diseases · doi:10.1016/s1079-9796(03)00031-7 · Cited by 60
Alterations of the AML1 transcription factor in human leukemia
Downing, J. R., Higuchi, M., Lenny, N. T., & Yeoh, A. E. J. (2000) · Seminars in Cell and Developmental Biology · doi:10.1006/scdb.2000.0183 · Cited by 64
Harada, H., Harada, Y., O’Brien, D. P., Rice, D. S., Naeve, C. W., & Downing, J. R. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3808 · Cited by 60
RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53
Wotton, S., Blyth, K., Kilbey, A., Jenkins, A., Terry, A., Bernardin, F., Friedman, A. D., Baxter, E. W., Neil, J. C., & Cameron, E. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207729 · Cited by 64
Fujita, Y., Nishimura, M., Taniwaki, M., Abe, T., & Okuda, T. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.4513 · Cited by 62
Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production
Geddis, A. E., & Kaushansky, K. (2004) · Current Opinion in Pediatrics · doi:10.1097/00008480-200402000-00005 · Cited by 62
The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells
Tonks, A., Pearn, L., Tonks, A. J., Pearce, L., Hoy, T., Phillips, S., Fisher, J., Downing, J. R., Burnett, A. K., & Darley, R. L. (2003) · Blood · doi:10.1182/blood-2002-06-1732 · Cited by 58
Nishimura, M., Fukushima‐Nakase, Y., Fujita, Y., Nakao, M., Toda, S., Kitamura, N., Abe, T., & Okuda, T. (2003) · Blood · doi:10.1182/blood-2003-06-2109 · Cited by 59
Osman, D., Gobert, V., Ponthan, F., Heidenreich, O. T., Haenlin, M., & Waltzer, L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902449106 · Cited by 60
Matsuno, N., Osato, M., Yamashita, N., Yanagida, M., Nanri, T., Fukushima, T., Motoji, T., KUSUMOTO, S., Towatari, M., Suzuki, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403160 · Cited by 60
RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML
Loke, J., Assi, S. A., Imperato, M. R., Ptasinska, A., Cauchy, P., Grabovska, Y., Soria, N. M., Raghavan, M., Delwel, H. R., Cockerill, P. N., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.005 · Cited by 56
Strout, M. P., Marcucci, G., Caligiuri, M. A., & Bloomfield, C. D. (1999) · Annals of Hematology · doi:10.1007/s002770050511 · Cited by 61
The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1
Frank, R. C., Sun, X., Berguido, F. J., Jakubowiak, A. J., & Nimer, S. D. (1999) · Oncogene · doi:10.1038/sj.onc.1202459 · Cited by 66
Lou, J., Cao, W., Bernardin, F., Ayyanathan, K., Rauscher, F. J., & Friedman, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1203588 · Cited by 60
CBFβ is critical for AML1-ETO and TEL-AML1 activity
Roudaia, L., Cheney, M. D., Manuylova, E., Chen, W., Morrow, M., Park, S., Lee, C.-T., Kaur, P., Williams, O., Bushweller, J. H., et al. (2009) · Blood · doi:10.1182/blood-2008-03-147207 · Cited by 59
Self-citationLin, S., Mulloy, J. C., & Goyama, S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-3233-2_11 · Cited by 60
Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cells
Nimer, S. D., & Moore, M. A. S. (2004) · Oncogene · doi:10.1038/sj.onc.1207673 · Cited by 64
Seed Versus Soil: The Importance of the Target Cell for Transgenic Models of Human Leukemias
Westervelt, P., & Ley, T. J. (1999) · Blood · doi:10.1182/blood.v93.7.2143 · Cited by 54
Modelling haematopoietic malignancies in the mouse and therapeutical implications
Bernardi, R., Grisendi, S., & Pandolfi, P. P. (2002) · Oncogene · doi:10.1038/sj.onc.1205313 · Cited by 62
Targeted therapies in myeloid leukemia
John, A. M., Thomas, N. S. B., Mufti, G. J., & Padua, R. A. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.11.006 · Cited by 62
Yan, M., Ahn, E.-Y. E., Hiebert, S. W., & Zhang, D. (2008) · Blood · doi:10.1182/blood-2008-04-153742 · Cited by 55
Self-citationVradii, D., Zaidi, S. K., Lian, J. B., van Wijnen, A. J., Stein, J. L., & Stein, G. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502130102 · Cited by 51
Marcucci, G., Caligiuri, M. A., & Bloomfield, C. D. (2000) · Cancer Investigation · doi:10.3109/07357900009012209 · Cited by 55
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities
Sinha, C., Cunningham, L., & Liu, P. (2015) · Seminars in Hematology · doi:10.1053/j.seminhematol.2015.04.002 · Cited by 54
Point Mutations of the RUNX1/AML1 Gene in Sporadic and Familial Myeloid Leukemias
Osato, M., Yanagida, M., Shigesada, K., & Itoa, Y. (2001) · International Journal of Hematology · doi:10.1007/bf02982056 · Cited by 53
Tonks, A. J., Tonks, A. J., Pearn, L., Pearce, L., Hoy, T. G., Couzens, S., Fisher, J., Burnett, A. K., & Darley, R. L. (2004) · Leukemia · doi:10.1038/sj.leu.2403396 · Cited by 58
Review: genetic models of acute myeloid leukaemia
McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2008) · Oncogene · doi:10.1038/onc.2008.16 · Cited by 57
Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1
Kamikubo, Y., Zhao, L., Wunderlich, M., Corpora, T., Hyde, R. K., Paul, T. A., Kundu, M., Garrett, L. J., Compton, S. T., Huang, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.022 · Cited by 51
The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor
Wildonger, J., & Mann, R. S. (2005) · Development · doi:10.1242/dev.01824 · Cited by 54
Geddis, A. E. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2006.04.003 · Cited by 47
Chromosomal translocation products engender new intracellular therapeutic technologies
Rabbitts, T. H., & Stocks, M. (2003) · Nature Medicine · doi:10.1038/nm0403-383 · Cited by 47
Pathways in blood and vessel development revealed through zebrafish genetics
Crosier, P. S., Kalev‐Zylinska, M. L., Hall, C. J., Flores, M. V., Horsfield, J. A., & Crosier, K. E. (2002) · The International Journal of Developmental Biology · doi:10.1387/ijdb.12141436 · Cited by 52
RUNX1: A MicroRNA Hub in Normal and Malignant Hematopoiesis
Rossetti, S., & Sacchi, N. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14011566 · Cited by 51
Histone acetylation: plants and fungi as model systems for the investigation of histone deacetylases
Graessle, S., Loidl, P., & Brosch, G. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000894 · Cited by 57
Cuenco, G. M., & Ren, R. (2004) · Oncogene · doi:10.1038/sj.onc.1207143 · Cited by 55
Chou, F., Wunderlich, M., Griesinger, A. M., & Mulloy, J. C. (2011) · Blood · doi:10.1182/blood-2010-01-264119 · Cited by 49
Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma
Kundu, M., Compton, S. T., Garrett-Beal, L. J., Stacy, T., Starost, M. F., Eckhaus, M., Speck, N. A., & Liu, P. P. (2005) · Blood · doi:10.1182/blood-2005-04-1447 · Cited by 48
Self-citationTransposon-generated ‘knock-out’ and ‘knock-in’ gene-targeting constructs for use in mice
Westphal, C. H., & Leder, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00224-7 · Cited by 44
Ren, R. (2002) · Oncogene · doi:10.1038/sj.onc.1206090 · Cited by 47
Cao, W., Adya, N., Britos-Bray, M. F., Liu, P., & Friedman, A. D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31534 · Cited by 46
Gu, X., Hu, Z., Ebrahem, Q., Crabb, J. S., Mahfouz, R. Z., Radivoyevitch, T., Crabb, J. W., & Saunthararajah, Y. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.562447 · Cited by 42
Mouse Chromosome Engineering for Modeling Human Disease
van der Weyden, L., & Bradley, A. (2006) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.7.080505.115741 · Cited by 47
Biology and therapy of secondary leukaemias
Dann, E. J., & Rowe, J. M. (2001) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2000.0119 · Cited by 42
Britos-Bray, M. F., Ramírez, M. R., Cao, W., Wang, X., Liu, P. P., Civin, C. I., & Friedman, A. D. (1998) · Blood · doi:10.1182/blood.v92.11.4344 · Cited by 44
Haploinsufficiency of Runx1/AML1 promotes myeloid features and leukaemogenesis in BXH2 mice
Yamashita, N., Osato, M., Huang, L., Yanagida, M., Kogan, S. C., 岩崎, 正., Nakamura, T., Shigesada, K., Asou, N., & Ito, Y. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05793.x · Cited by 41
Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia
Üstün, C., & Marcucci, G. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000124 · Cited by 38
OGG1 is a novel prognostic indicator in acute myeloid leukaemia
Liddiard, K., Hills, R. K., Burnett, A. K., Darley, R. L., & Tonks, A. (2009) · Oncogene · doi:10.1038/onc.2009.462 · Cited by 42
Nick, H. J., Kim, H., Chang, C., Harris, K. W., Reddy, V., & Klug, C. A. (2011) · Blood · doi:10.1182/blood-2011-02-338228 · Cited by 39
Investigating human leukemogenesis: from cell lines to in vivo models of human leukemia
Kennedy, J. A., & Barabé, F. (2008) · Leukemia · doi:10.1038/leu.2008.206 · Cited by 53
Fukushima‐Nakase, Y., Naoe, Y., Taniuchi, I., Hosoi, H., Sugimoto, T., & Okuda, T. (2005) · Blood · doi:10.1182/blood-2004-08-3372 · Cited by 38
Transcriptional Regulation of ILT Family Receptors
Nakajima, H., Asai, A., Okada, A., Ping, L., Hamajima, F., Sata, T., & Isobe, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6611 · Cited by 39
Worming out the biology of Runx
Nimmo, R. A., & Woollard, A. C. S. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2007.11.002 · Cited by 43
The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Levantini, E., Di Ruscio, A., Ebralidze, A. K., Bach, C., Zhang, H., Zhang, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550855 · Cited by 36
Self-citationLobato, M. N., Metzler, M., Drynan, L. F., Forster, A., Pannell, R., & Rabbitts, T. H. (2008) · JNCI Monographs · doi:10.1093/jncimonographs/lgn022 · Cited by 35
Nakao, M., Horiike, S., Fukushima‐Nakase, Y., Nishimura, M., Fujita, Y., Taniwaki, M., & Okuda, T. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04966.x · Cited by 34
“…as AML1-MTG8 caused by t(8;21), generally result in strong dominant-negative alleles, such that genome-manipulated mice heterozygous for the knock-in allele of the chimaeric gene die in utero, thus manifesting a phenocopy of the simple knockout of this gene (Yergeau et al, 1997; Okuda et al, 1998).”
BackgroundJin, W., Wu, K., Yz, L., Yang, W.-T., Zou, B., Zhang, F., Zhang, J., & Wang, K.-K. (2012) · Oncogene · doi:10.1038/onc.2012.204 · Cited by 36
Nafria, M., Keane, P., Ng, E. S., Stanley, E. G., Elefanty, A. G., & Bonifer, C. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107691 · Cited by 34
Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera
Huang, G., Shigesada, K., Wee, H., Liu, P. P., Osato, M., & Ito, Y. (2003) · Blood · doi:10.1182/blood-2003-07-2188 · Cited by 36
Lo, M., Peterson, L. F., Yan, M., Cong, X., Jin, F., Shia, W.-J., Matsuura, S., Ahn, E.-Y. E., Komeno, Y., Ly, M., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395335 · Cited by 39
Self-citationShimada, H., Ichikawa, H., & Ohki, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402465 · Cited by 34
Miller, J., Stacy, T., Liu, P. P., & Speck, N. A. (2001) · Blood · doi:10.1182/blood.v97.8.2248 · Cited by 36
Self-citationMolecular targets and the treatment of myeloid leukemia
Ikeda, A. K., Shankar, D. B., Watanabe, M., Tamanoi, F., Moore, T. B., & Sakamoto, K. M. (2006) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2006.03.011 · Cited by 33
Kummalue, T., Lou, J., & Friedman, A. D. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.23.8278-8291.2002 · Cited by 33
Metadata
- Authors
- Yergeau, D. A., Hetherington, C. J., Wang, Q., Zhang, P., Sharpe, A. H., Binder, M., Marín-Padilla, M., Tenen, D. G., Speck, N. A., & Zhang, D.-E.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Dartmouth College (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Dong-Er
- Venue
- Nature Genetics
- Published
- 1997-03
- Volume
- 15
- Issue
- 3
- Pages
- 303-306
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2054210423
- Cited by
- 346
- References
- 32
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 3 · 2021: 1 · 2020: 4 · 2019: 4 · 2018: 2 · 2017: 12 · 2016: 4 · 2015: 10 · 2014: 5 · 2013: 7 · 2012: 15
- FWCI
- 13.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns022897-10)
- National Cancer Institute (CA 41456, R01CA041456)
- National Institute of Neurological Disorders and Stroke (NS22897)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P030AR42689)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- AML1-ETO fusion gene, acute myeloid leukemia, embryonic lethality, macrophage differentiation, leukemogenesis, CBFB
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Animals, Chimera, Chromosome Mapping, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Cloning, Molecular, Crosses, Genetic, DNA-Binding Proteins, Exons, Female, Fetal Death, Hematopoiesis, Genetic Carrier Screening, Humans, Leukemia, Myeloid, Liver, Male, Mice, Inbred C57BL, Mice, Mutant Strains, Proto-Oncogene Proteins, Transcription Factors, Translocation, Genetic, Yolk Sac, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.